APRIL inhibitors(Tumor necrosis factor ligand superfamily member 13 inhibitors), BAFF inhibitors(B-cell-activating factor/B lymphocyte stimulator inhibitors)

Therapeutic Areas

Immune System DiseasesUrogenital DiseasesOther Diseases

Active Indication

Glomerulonephritis, IGAGlomerular diseaseNephrotic Syndrome

Inactive Indication

Clinically isolated syndromeLupus NephritisMultiple sclerosis relapse+ [4]

Originator Organization

ZymoGenetics, Inc.

Active Organization

Vera Therapeutics, Inc.Merck Serono SA

Inactive Organization

License Organization

Vera Therapeutics, Inc.

ZymoGenetics, Inc.

+ [1]

Drug Highest PhasePhase 3

First Approval Date-

RegulationBreakthrough Therapy (United States), Orphan Drug (European Union), Orphan Drug (Japan)

Structure/Sequence

Sequence Code 102889

Source: *****

Clinical Trials associated with Atacicept

NCT06983028

/ RecruitingPhase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)

The purpose of this study is to evaluate the safety and tolerability of atacicept in adult and adolescent participants and to measure the effect in reducing proteinuria and preserving renal function.

Start Date07 Jul 2025

Sponsor / Collaborator

Vera Therapeutics, Inc.

CTRI/2025/05/086952

/ Not yet recruitingNot Applicable

A Multicenter, Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Start Date30 Jun 2025

Sponsor / Collaborator

Vera Therapeutics, Inc.

NCT07020923

/ RecruitingPhase 2

A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients With IgAN

This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept

Start Date29 May 2025

Sponsor / Collaborator

Vera Therapeutics, Inc.

100 Clinical Results associated with Atacicept

100 Translational Medicine associated with Atacicept

100 Patents (Medical) associated with Atacicept

129

Literatures (Medical) associated with Atacicept

01 Apr 2025·JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy

Article

Author: Brenner, Robert M. ; Jha, Vivekanand ; Maes, Bart ; Wei, Xuelian ; Tesař, Vladimír ; Kim, Sung Gyun ; Barbour, Sean J. ; Phoon, Richard K.S. ; Eren, Necmi ; Singh, Harmeet ; Barratt, Jonathan ; Floege, Jürgen ; Lafayette, Richard ; Cooper, Kerry

Key Points:

Participants who completed a 36-week double-blind study of atacicept were eligible for a 60-week, open-label extension study.Atacicept 96-week treatment resulted in sustained reductions in galactose-deficient IgA1, hematuria, and urine protein-creatinine ratio.The slope of the eGFR was similar to that observed in the general population without kidney disease.

Background:

B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) play key roles in the pathogenesis of IgA nephropathy. Atacicept is a novel fully humanized fusion protein, self-administered at home by subcutaneous injection, that binds and inhibits BAFF and APRIL. By inhibiting BAFF and APRIL, atacicept targets the underlying B-cell–mediated pathogenesis driving disease progression. This study evaluated the long-term efficacy and safety of atacicept in patients with IgA nephropathy over 96 weeks.

Methods:

Participants with IgA nephropathy who received atacicept (25, 75, or 150 mg) or placebo in a 36-week phase 2b, randomized, blinded trial were enrolled in an open-label extension study and received atacicept 150 mg for an additional 60 weeks. Key efficacy outcomes were changes in galactose-deficient IgA1 (Gd-IgA1), percentage of participants with hematuria, urine protein-creatinine ratio (UPCR), and eGFR over 96 weeks. Long-term safety data were also evaluated.

Results:

There were 113 participants (67 [59%] male; 46 [41%] female) who ranged in age from 18 to 67 years who received ≥1 atacicept dose. Over 96 weeks, safety data demonstrated that atacicept was generally well tolerated. There were also sustained reductions (mean±SEM) in Gd-IgA1 (−66%±2%), percentage of participants with hematuria (−75%; 95% confidence intervals, −87 to −59; in participants with baseline hematuria), and UPCR (−52%±5%). The mean annualized slope of eGFR was −0.6±0.5 ml/min per 1.73 m2 through 96 weeks.

Conclusions:

Atacicept was well tolerated over the duration of the study. Atacicept treatment reduced Gd-IgA1, hematuria, and UPCR with stabilization of eGFR through 96 weeks.

Clinical Trial registry name and registration number::

Atacicept in Subjects with IgA Nephropathy (ORIGIN 2), NCT04716231.

Podcast:

This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2024_10_26_KTS_October2024.mp3

19 Dec 2024·Iranian Journal of Kidney Diseases

TACI Ig Fusion Protein Inhibits TLR4/MyD88/NF-κB Pathway Alleviates Renal Injury in IgA Nephropathy Rats.

Article

Author: Cheng, Yue ; Chen, Peng ; Sun, Jianhua ; Wang, Caili ; Zhang, Wei ; Li, Zengyan ; Chen, Xinnan

INTRODUCTION:

To evaluate the impact of TACI fusion protein (TACI-Ig) on IgA nephropathy (IgAN) in rats, and to explore its mechanism and relationship with TLR4/MyD88/NF-κB pathway.

METHOD:

Sprague Dawley(SD)rats were divided into six groups: control, model, TACI-Ig low dose (TACI-Ig-L), medium dose (TACI-Ig-M), high dose (TACI-Ig-H), and prednisone acetate (PAT) group. The control group and model group received physiological saline injections, while the TACI-Ig groups were administered doses of 7.18, 14.36, and 28.72 mg/kg of TACI-Ig, respectively. PAT group was pretreated with prednisone acetate. After 8 weeks, kidney weight/body weight ratios, 24-hour urine protein (24 h UP), serum creatinine (SCr), and blood urea nitrogen (BUN) levels were measured. Additionally, concentrations of B cell activating factor (BAFF), APRIL, and Gd-IgA1 were evaluated by using ELISA. Pathological changes in kidney tissues were scored, and TLR4, MyD88, NF-κB expression levels were detected through western blot (WB) and RT-qPCR.

RESULTS:

Renal function assessments showed that the IgAN model group exhibited increased in 24 h UP, SCr, BUN, and elevated serum levels of BAFF, APRIL, Gd-IgA1, alongside higher TLR4/MyD88/NF-κB protein expression. TACI-Ig treatment significantly reduced proteinuria, SCr, BUN, levels of BAFF, APRIL, and Gd-IgA1 in IgAN rats. Pathologically, TACI-Ig ameliorated glomerular mesangial deposition and fibrosis. It also inhibited TLR4/MyD88/NF-κB protein expression, demonstrating anti-inflammatory and immune regulatory effects.

CONCLUSIONS:

TACI-Ig mitigates renal injury in IgAN rats by reducing inflammatory infiltration and IgA deposition and suppressing the pathway of TLR4/MyD88/NF-κB, offering data for developing effective treatments for IgAN.

01 Nov 2024·International Journal of Clinical Oncology

Current status of BAFF targeting immunotherapy in B-cell neoplasm

Review

Author: Tagami, Nami ; Yuda, Junichiro ; Goto, Yasuyuki

Abstract:

B-cell activating factor belonging to the TNF family (BAFF), also known as B-lymphocyte stimulator (BLyS), plays a crucial role in B-cell development. It has multiple receptors, including BCMA, TACI, and BAFF-R, with diverse roles in different cell types. BAFF induces B-cell proliferation and immunoglobulin secretion, and acts as a survival factor for immature, naive, and activated B cells. Consequently, BAFF-deficient mice often show suppressed humoral responses, while BAFF-overexpressing mice show the higher number of mature B cells and may develop autoimmune-like manifestations and B-cell lymphoproliferative diseases. Elevated BAFF levels are also associated with various hematological malignancies, and its expression correlates with disease progression in some cases. Therefore, BAFF-targeted therapies, such as belimumab, atacicept, and tabalumab, are being explored in clinical trials for conditions like chronic lymphocytic leukemia (CLL) and multiple myeloma. Belimumab, an anti-BAFF monoclonal antibody, is being investigated in combination with rituximab/venetoclax for CLL. Atacicept, a decoy receptor for BAFF and APRIL, showed tolerability in a phase 1b trial for CLL. Tabalumab, another monoclonal antibody targeting BAFF, did not demonstrate significant efficacy in a phase 2 study for relapsed/refractory multiple myeloma. BAFF ligand-based CAR-T cells are designed to target BAFF receptors and show promise in preclinical studies, particularly for B-cell malignancies. The review emphasizes the importance of understanding the roles of BAFF and its receptors in the microenvironment of hematologic malignancies. Targeting BAFF and its receptors presents potential therapeutic avenues, and ongoing clinical trials provide valuable insights.

107

News (Medical) associated with Atacicept

05 Aug 2025

·www.globenewswire.com

Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

On track to submit a Biologics License Application (BLA) for accelerated approval of atacicept to U.S. FDA in Q4 2025; potential commercial launch in 2026Announced positive primary endpoint results from the ongoing ORIGIN Phase 3 trialInitiated the PIONEER trial to investigate atacicept in a broader IgAN patient cohort and multiple autoimmune glomerular diseasesExpected to present full primary endpoint results from the ORIGIN 3 trial at a medical congress in Q4 2025 BRISBANE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the second quarter ended June 30, 2025. “Our team delivered exciting new clinical results from our pivotal ORIGIN 3 trial in the second quarter of 2025, which were consistent with or better than our previous trials for atacicept in patients with IgAN. Based on the strength of the overall data accumulated for atacicept over the past few years, we are excited to move ahead with our BLA submission to the U.S. FDA for accelerated approval. We anticipate submitting the BLA in the fourth quarter of 2025, with an expected commercial launch in 2026,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. “Atacicept has the potential to advance the standard of care in IgAN as the first dual BAFF/APRIL inhibitor. We are thrilled for the potential of atacicept as a possible disease-modifying therapy to address the unmet medical needs of IgAN patients.” Second Quarter 2025 and Recent Business Highlights Announced positive 36-week data from the ongoing pivotal ORIGIN 3 trial of atacicept in patients with IgA Nephropathy (IgAN), including: 46% reduction from baseline in proteinuria for participants treated with atacicept, as measured by 24-hour urine protein-to-creatinine ratio (UPCR); primary endpoint achieved with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p<0.0001)Atacicept-treated participants demonstrated results across other prespecified endpoints that were consistent with or better than those previously observed in the ORIGIN Phase 2b trialSafety profile of atacicept across ORIGIN program appears favorable, and comparable to placebo Completed full enrollment in the ongoing ORIGIN 3 trialEnrolling participants in the ORIGIN Extend study, which provides ORIGIN study participants with extended access to atacicept until commercial availability in their region, and captures longer-term safety and efficacy dataInitiated the PIONEER trial to evaluate atacicept in expanded IgAN populations, anti-PLA2R positive primary membranous nephropathy (pMN), and anti-nephrin positive focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) patientsStrengthened the Company’s financial positioning with a new credit facility of up to $500 million of term loans with existing partner Oxford Finance LLC, extending the Company’s cash runway well beyond potential commercial launch of atacicept Anticipated Upcoming Milestones Submission of a BLA for atacicept in IgAN to the U.S. FDA in Q4 2025 for accelerated approval; potential commercial launch in 2026Presentation of the full 36-week results from the pivotal ORIGIN 3 trial expected at a medical congress in Q4 2025Initial results from the PIONEER Phase 2 basket trial expected in Q4 2025Pivotal ORIGIN 3 study expected to be completed in 2027 Financial Results for the Quarter Ended June 30, 2025For the quarter ended June 30, 2025, Vera reported a net loss of $76.5 million, or a net loss per diluted share of $1.20, compared to a net loss of $33.7 million, or a net loss per diluted share of $0.62, for the quarter ended June 30, 2024. During the six months ended June 30, 2025, net cash used in operating activities was $109.2 million, compared to $58.6 million for the same period last year. Vera reported $556.8 million in cash, cash equivalents, and marketable securities as of June 30, 2025, which combined with its undrawn debt facility, Vera believes to be sufficient to fund operations through potential approval and U.S. commercial launch of atacicept and beyond. About Atacicept Atacicept is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgAN, other autoimmune kidney diseases and lupus nephritis. The ORIGIN Phase 2b clinical trial of atacicept in IgAN met its primary and key secondary endpoints, with statistically significant and clinically meaningful proteinuria reductions and stabilization of eGFR versus placebo through 36 weeks. The safety profile during the randomized period was comparable between atacicept and placebo. Through 96 weeks, atacicept demonstrated further improvements in Gd-IgA1, hematuria, and proteinuria, as well as stabilization of eGFR reflecting a profile consistent with that of the general population without IgAN. Atacicept has received FDA Breakthrough Therapy Designation for the treatment of IgAN, which reflects the FDA’s determination that, based on an assessment of data from the ORIGIN Phase 2b clinical trial, atacicept may demonstrate substantial improvement on a clinically significant endpoint over available therapies for patients with IgAN. Vera believes atacicept is positioned for best-in-class potential, targeting B cells to reduce autoantibodies and having been administered to more than 1,500 patients in clinical trials across different disease areas. About VeraVera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both BAFF and APRIL, which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com Forward-looking StatementsStatements contained in this press release regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, Vera’s plans to submit a Biologics License Application to the U.S. FDA for accelerated approval and to potentially receive FDA approval for atacicept in IgAN and launch it commercially, present full primary endpoint results from the ORIGIN 3 trial at a medical congress, obtain initial results from the PIONEER Phase 2 basket trial, and complete the ORIGIN 3 study, as well as statements regarding the timing of each such event; the ability of atacicept to advance the standard of care in IgAN and to address the unmet medical needs of IgAN patients; Vera’s ability to fund its operations through potential approval and U.S. commercial launch of atacicept; and Vera’s plans, commitments, aspirations and goals under the caption “About Vera”. Because such statements are subject to risk and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believe,” “plan,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera’s business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. For more information, please contact: Investor Contact:Joyce AllaireLifeSci Advisors212-915-2569jallaire@lifesciadvisors.com Media Contact:Debra CharlesworthVera Therapeutics415-854-8051corporatecommunications@veratx.com VERA THERAPEUTICS, INC.Condensed Statements of Operations and Comprehensive Loss(in thousands, except share and per share amounts)(Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Operating expenses: Research and development$58,195 $29,311 $99,473 $52,511 General and administrative 21,946 8,032 37,862 15,944 Total operating expenses 80,141 37,343 137,335 68,455 Loss from operations (80,141) (37,343) (137,335) (68,455)Other income, net 3,610 3,635 9,110 6,364 Net loss$(76,531) $(33,708) $(128,225) $(62,091)Change in unrealized gain/loss on marketable securities$(127) $(277) $134 $(700)Comprehensive loss$(76,658) $(33,985) $(128,091) $(62,791)Net loss per share attributable to common stockholders, basic and diluted$(1.20) $(0.62) $(2.01) $(1.17)Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 63,789,303 54,728,552 63,730,756 52,850,242 VERA THERAPEUTICS, INC.Condensed Balance Sheets(in thousands) June 30, December 31, 2025 2024 (unaudited) Assets Current assets: Cash, cash equivalents and marketable securities$556,827 $640,852 Prepaid expenses and other current assets 14,527 10,366 Total current assets 571,354 651,218 Operating lease right-of-use assets 2,471 3,372 Other noncurrent assets 4,703 1,091 Total assets$578,528 $655,681 Liabilities and stockholders' equity Current liabilities: Accounts payable$13,157 $7,665 Operating lease liabilities 855 1,483 Accrued expenses and other liabilities, current 19,542 16,223 Total current liabilities 33,554 25,371 Long-term debt 74,464 50,687 Operating lease liabilities, noncurrent 2,233 2,468 Total liabilities 110,251 78,526 Stockholders' equity Common stock 64 64 Additional paid-in-capital 1,057,161 1,037,948 Accumulated other comprehensive income 527 393 Accumulated deficit (589,475) (461,250)Total stockholders' equity 468,277 577,155 Total liabilities and stockholders' equity$578,528 $655,681

Clinical ResultPhase 2Breakthrough TherapyPhase 3License out/in

25 Jul 2025

·www.fiercebiotech.com

Memo pushes kidney drug to phase 3 despite primary endpoint miss

Memo Therapeutics will share more phase 2 data at the World Transplant Congress next month. \n A phase 2 trial of Memo Therapeutics’ kidney transplant drug candidate has missed its primary endpoint, adding to the list of setbacks in the indication. But the Swiss biotech saw promise in other aspects of the data set and outlined plans to move into phase 3.The phase 2 trial tested Memo’s anti-BK polyomavirus antibody potravitug. Investigators randomized 95 kidney transplant recipients infected with the virus to receive potravitug or placebo. At Week 20, the proportion of patients with undetectable levels of the virus in the blood was statistically no higher in the treatment arm than in the control group, causing the trial to miss its primary endpoint.However, Memo pointed to success against other measures to make the case for further development of the antibody. The treatment group had significantly higher viral response with resolution of biopsy-proven BK polyomavirus nephropathy (BKPyVAN). “This histological improvement in BKPyVAN indicated resolution of the underlying disease, decreasing from 51.2% at baseline to 31.6% at Week 20 in the treatment group, while no change was observed in the placebo group,” Memo said in a statement. Memo reported no treatment-related serious adverse events or withdrawals due to adverse events. The biotech will share more phase 2 data at the World Transplant Congress next month. In parallel, Memo is preparing to talk to regulators later this year about the design of a planned phase 3 program. Potravitug has a fast-track designation from the FDA.No drugs against the virus are approved by the FDA. Vera Therapeutics has a rival candidate, MAU868, but progress stalled after it completed phase 2 back in 2022. The company is focused on bringing another asset, atacicept, to market. AlloVir was developing posoleucel for use against BK virus, wrapping up a phase 2 trial in 2022, but phase 3 failures led the company to enter into a reverse merger last year.

Phase 3Fast TrackPhase 2Clinical Result

06 Jun 2025

·pharma.economictimes.indiatimes.com

Otsuka's kidney disease drug shows over 50% reduction in protein in urine

Bengaluru: Otsuka 's experimental drug for a type of kidney disease showed over 50 per cent reduction in protein in patients' urine in a late-stage trial, the Japan-based company said on Friday. Patients treated with the therapy, sibeprenlimab , achieved a 51.2% reduction in proteinuria at nine months of treatment when compared to placebo. The company is seeking approval for the therapy, a monoclonal antibody, to treat Immunoglobulin A Nephropathy (IgAN), also known as Berger's disease , which causes abnormal protein buildup in the kidneys and could eventually lead to the organ's failure. It was the largest IgAN trial to date, which consisted of about 510 adult patients the company said. The U.S. health regulator is set to decide on the marketing application of the therapy by November 28. Shares of rival Vera Therapeutics fell over 31% in premarket trading. Vera's experimental drug, atacicept, reduced protein levels in patients' urine by 46%, compared with a 7% reduction with a placebo, meeting the main goal of the 428-patient late-stage study, the company said on Monday. (Reporting by Sriparna Roy and Siddhi Mahatole in Bengaluru)

Clinical ResultClinical Study

100 Deals associated with Atacicept

External Link

KEGG	Wiki	ATC	Drug Bank
D09704	Atacicept	-	DB06399

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glomerulonephritis, IGA	Phase 3	United States	Vera Therapeutics, Inc.	29 Jun 2023
Systemic Lupus Erythematosus	Phase 3	United States	Merck KGaA	01 Jan 2008
Systemic Lupus Erythematosus	Phase 3	Argentina	Merck KGaA	01 Jan 2008
Systemic Lupus Erythematosus	Phase 3	Australia	Merck KGaA	01 Jan 2008
Systemic Lupus Erythematosus	Phase 3	Austria	Merck KGaA	01 Jan 2008
Systemic Lupus Erythematosus	Phase 3	Bulgaria	Merck KGaA	01 Jan 2008
Systemic Lupus Erythematosus	Phase 3	Croatia	Merck KGaA	01 Jan 2008
Systemic Lupus Erythematosus	Phase 3	Czechia	Merck KGaA	01 Jan 2008
Systemic Lupus Erythematosus	Phase 3	France	Merck KGaA	01 Jan 2008
Systemic Lupus Erythematosus	Phase 3	Germany	Merck KGaA	01 Jan 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04716231 (ORIGIN, GlobeNewswire) Manual	Phase 2	Glomerulonephritis, IGA	116	Atacicept	fggxtzhrds(lixcmomnfo) = lpszxgxprx vwxrfgynyy (gspfwluawn ) View more	Positive	26 Oct 2024
				Placebo	-
ISN WCN2024	Not Applicable	Glomerulonephritis, IGA	-	Atacicept 150 mg	vtuagisjdg(ogcwswfzzo) = jafolyctbk mvlkaapfey (awcvmqktdr )	-	01 Apr 2024
				Placebo	vtuagisjdg(ogcwswfzzo) = cbshktxsrp mvlkaapfey (awcvmqktdr )
NCT04716231 (ORIGIN, Literature) Manual	Phase 2	Glomerulonephritis, IGA	116	atacicept 25 mg	zygqmbcixm(ozdiqqtjbo) = similar across the atacicept dose groups and placebo. mravbqbosd (apdcxdzilt )	Positive	27 Mar 2024
				atacicept 75 mg
NCT04716231 (ORIGIN, GlobeNewswire) Manual	Phase 2	Glomerulonephritis, IGA	-	Atacicept	pkbhymzcyl(jyrfugelxl) = met its primary endpoint djoufdsirl (vdlvcoteun ) Met View more	Positive	08 Jan 2024
				Placebo
NCT04716231 (ORIGIN \| JANUS, GlobeNewswire) Manual	Phase 2	Glomerulonephritis, IGA	-	atacicept (JANUS)	veiwjncaru(qwkhtaywpy) = Through the randomized, placebo-controlled period, infections were balanced between atacicept and placebo in both the Phase 2a JANUS and Phase 2b ORIGIN studies. xstspdlsof (zoacwodfbl )	Positive	04 Nov 2023
				placebo (JANUS)
NCT02808429 (Phase II study, CTgov)	Phase 2	Glomerulonephritis, IGA	16	Placebo (Placebo)	ifwdlankak = qhvwqylraq ulijnpavan (yewucuszze, bkdetotdfi - nuqewczsro) View more	-	25 Feb 2021
				Atacicept 25 mg (Atacicept 25 mg)	ifwdlankak = yszxdvlgfl ulijnpavan (yewucuszze, jdfxidrnfc - golvxbwgjw) View more
NCT02070978 (ADDRESS II, Pubmed \| Rheumatology (Oxford))	Phase 2	Systemic Lupus Erythematosus	253	Atacicept 75 mg	hlxnxkkucy(elkjbhuvaa) = ispzlmqnaw fprifvnsuj (ybzrttgdoz ) View more	-	06 Feb 2021
				Atacicept 150 mg	hlxnxkkucy(elkjbhuvaa) = dvgwxacyoy fprifvnsuj (ybzrttgdoz ) View more
NCT02808429 (Phase II study, ERA2020)	Phase 2	Proteinuria \| Glomerulonephritis, IGA Gd-IgA1	-	Placebo	aidctrpsbd(ihzyvetqts) = yhmkoenoba lnyiycnqwj (fkcfcyvtqy )	Positive	06 Jun 2020
				Atacicept 25mg	aidctrpsbd(ihzyvetqts) = yrxbtxttgf lnyiycnqwj (fkcfcyvtqy )
NCT01972568 (ADDRESS II, Pubmed \| Rheumatology (Oxford))	Phase 2	Systemic Lupus Erythematosus	306	Atacicept 150 mg	wcemcnksss(cggnfuigmj): OR = 3.82 (95% CI, 1.44 - 10.15), P-Value = 0.007 View more	-	27 Feb 2020
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis